Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,019,822
  • Shares Outstanding, K 42,449
  • Annual Sales, $ 182,950 K
  • Annual Income, $ -115,550 K
  • EBIT $ -87 M
  • EBITDA $ -90 M
  • 60-Month Beta 0.59
  • Price/Sales 7.92
  • Price/Cash Flow N/A
  • Price/Book 9.33

Options Overview Details

View History
  • Implied Volatility 55.68% (+4.46%)
  • Historical Volatility 25.46%
  • IV Percentile 43%
  • IV Rank 35.92%
  • IV High 87.29% on 01/22/25
  • IV Low 37.97% on 08/20/25
  • Expected Move (DTE 33) 7.91 (11.11%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 220
  • Volume Avg (30-Day) 241
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 5,414
  • Open Int (30-Day) 5,294
  • Expected Range 63.24 to 79.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 4
  • High Estimate 0.06
  • Low Estimate -0.68
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +73.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
70.99 +0.21%
on 01/16/26
84.07 -15.38%
on 12/24/25
-7.14 (-9.12%)
since 12/16/25
3-Month
65.30 +8.94%
on 10/24/25
85.25 -16.55%
on 12/09/25
-3.83 (-5.11%)
since 10/16/25
52-Week
38.51 +84.73%
on 08/01/25
85.25 -16.55%
on 12/09/25
+24.22 (+51.62%)
since 01/16/25

Most Recent Stories

More News
Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5 th Annual Ophthalmology...

TARS : 71.14 (-3.41%)
Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2 nd Annual Healthcare...

TARS : 71.14 (-3.41%)
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Delivered quarterly  XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter...

TARS : 71.14 (-3.41%)
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4,...

TARS : 71.14 (-3.41%)
Bank of America Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $85.00. The company’s shares closed yesterday at $69.75.Elevate...

TARS : 71.14 (-3.41%)
Bank of America Securities Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $80.00. The company’s shares closed yesterday at $58.77.Elevate...

TARS : 71.14 (-3.41%)
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: ...

TARS : 71.14 (-3.41%)
3 Biotech Catalysts Present Major Opportunity

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

BSX : 88.07 (-2.18%)
TARS : 71.14 (-3.41%)
ARQT : 25.85 (-1.93%)
Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Record quarterly net product sales of $102.7 million achieved within two years of our  XDEMVY ® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients,...

TARS : 71.14 (-3.41%)
Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6,...

TARS : 71.14 (-3.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 76.20
2nd Resistance Point 75.13
1st Resistance Point 73.13
Last Price 71.14
1st Support Level 70.07
2nd Support Level 69.00
3rd Support Level 67.00

See More

52-Week High 85.25
Last Price 71.14
Fibonacci 61.8% 67.40
Fibonacci 50% 61.88
Fibonacci 38.2% 56.36
52-Week Low 38.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar